GEN Exclusives

More »

GEN News Highlights

More »
Jul 7, 2010

Shire’s Transdermal Patch for ADHD Gets FDA Thumbs Up for Use in Adolescents

  • FDA has cleared Shire’s Daytrana® transdermal patch for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents aged 13-17 years. The methylphenidate patch system is already cleared in the U.S. for the treatment of children aged 6-12 years.

    Daytrana is indicated for use as part of a total treatment program for ADHD that can include psychological, educational, and social measures.

    Approval of Daytrana for the new age group is based on data from a Phase IIIb trial in 217 adolescents diagnosed with ADHD. Shire said the results showed use of the patch treatment led to significant reductions in the ADHD Rating Scale-IV total score from baseline compared with treatment using placebo.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?